… After treatment, there was incomplete depletion of LN B cells. There was a significant …
of the different B cell subsets after two rituximab infusions was changed in favour of IgD − …

… Indeed, treatment of patients with RA with depleting … clinical and serological biomarkers
with the arthritis hazard was … number of B cells was observed within 4 weeks after treatment in …

… In this study, we aimed to explore changes in serologic parameters … following B lymphocyte
depletion in RA and SLE patients, along with their effects on the activity of other immune cells …

… -40 in RA and its decrease following B cell depleting therapy. … imply its potential involvement
in RA development. Moreover, … B Cell Depletion Therapy on Serological Evidence of B Cell …

… the following scenario based on the role of T-helper cells in … shown to effectively deplete
activated B cells, which could be … Therapeutic success with rituximab may be related in part to …

… changes in the numbers of peripheral Treg and Th17 cells. … circulating T cell subpopulations
before and after treatment with … suggest that B cell depletion in patients with RA significantly …

… of therapies available to treat rheumatoid arthritis (RA), predicting response to therapy …
post-translational modifications can lead to loss of tolerance with subsequent asymptomatic …

… B lymphocyte depletion levels on days 30 and 90 after the first … B-cell depletion therapy on
serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis …

… changes in autoantibody levels following treatment … diseases, these serological changes in
RA may hold promise as an … underlying the B cell autoimmune response in RA and its role in …

… B cell depletion therapy further highlights the pathogenic significance of B cells in RA (5–7). …
pathways on human B cells remain unclear as careful longitudinal studies after anti-TNF …